Since hDT806 treatment upregulated NF-κB p65 activity and NF-κB as a master transcription factor of inflammation and immunity is emerging as a key positive regulator of programmed death ligand 1 (PDL1) expression in cancer43, we assessed whether this effect of hDT806 on p65 would result in any changes in PDL1, one of the most extensively studied inhibitory immune checkpoints due to its critical role in cancer immunotherapy. Here, NFKB1 is linked to cancer.